Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

Condition:   Celiac Disease Interventions:   Drug: Latiglutenase;   Other: Placebo Sponsors:   Immunogenics, LLC;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting

Source: ClinicalTrials.gov - January 28, 2020 Category: Research Source Type: clinical trials